glp1versus

Foundayo vs Zepbound

orforglipron (GLP-1 receptor agonist (oral small-molecule)) vs tirzepatide (Dual GIP and GLP-1 receptor agonist) — a complete side-by-side comparison.

Eli Lilly and CompanyEli Lilly

Foundayo weight loss

12.4%

Zepbound weight loss

22.5%

Foundayo dosing

Once daily

Zepbound dosing

Once weekly

Reviewed by Dr. Elena Vance, DOLast reviewed 11 sources cited

Quick Summary

Foundayo (orforglipron) and Zepbound (tirzepatide) are both incretin-based therapies. In clinical trials, Zepbound showed greater weight loss (22.5% vs 12.4%).

See the comparison table below for detailed side-by-side data.

Foundayo vs Zepbound: Full Comparison

FeatureFoundayo(orforglipron)Zepbound(tirzepatide)
Active Ingredientorforgliprontirzepatide
Drug ClassGLP-1 receptor agonist (oral small-molecule)Dual GIP and GLP-1 receptor agonist
ManufacturerEli Lilly and CompanyEli Lilly
FDA Approved2026-04-012023-11-08
Approved Indications
  • Chronic weight management in adults with obesity (BMI >=30 kg/m^2), or overweight (BMI >=27 kg/m^2) with at least one weight-related comorbid condition, as an adjunct to a reduced-calorie diet and increased physical activity
  • Chronic weight management in adults with BMI ≥30 or ≥27 with at least one weight-related comorbidity (adjunct to diet and exercise)
  • Treatment of moderate-to-severe obstructive sleep apnea in adults with obesity (December 20, 2024)
Routeoralsubcutaneous injection
FrequencyOnce dailyOnce weekly
Starting Dose3 mg once daily2.5 mg weekly
Maintenance Dose12 mg or 36 mg once daily5 mg, 10 mg, or 15 mg weekly
Max Dose36 mg once daily15 mg weekly
Weight Loss (%)12.4%22.5%
A1C ReductionN/A (not indicated for diabetes)N/A (not indicated for diabetes)
Key TrialATTAIN-1 (72 weeks)SURMOUNT-1 / SURMOUNT-5 (head-to-head vs semaglutide) (72 weeks)
List PricePricing announced at U.S. launch (April 2026); confirm with LillyDirect$1,060-$1,176/month
With InsuranceFormulary coverage evolving; many commercial plans expected to require prior authorization$25-$250/month (varies; weight-loss coverage is limited)
Savings CardEli Lilly savings program details emerging via LillyDirect$25/month (Lilly savings card, commercially insured)

Side Effects: Foundayo vs Zepbound

Side EffectFoundayoZepbound
Nausea21-27%24-33%
Diarrhea15-20%18-25%
Vomiting10-16%10-18%
Constipation8-14%13-17%
Indigestion/dyspepsia6-10%Not reported
Abdominal pain5-9%10-14%
Headache5-8%Not reported
Fatigue4-7%Not reported
Hair loss3-5%5-6%
Pancreatitis (rare)<0.5%<1%
DyspepsiaNot reported7-10%
Injection site reactionNot reported3-7%
Gallbladder eventsNot reported1.6%

Severity scale: 1 (mild) to 5 (serious). Based on FDA prescribing information and clinical trial data.

Related Comparisons

Foundayo vs OzempicZepbound vs OzempicFoundayo vs WegovyZepbound vs WegovyFoundayo vs MounjaroZepbound vs MounjaroFoundayo vs RybelsusZepbound vs Rybelsus

Frequently Asked Questions

Sources & References

FDA & Regulatory

  1. Foundayo FDA Drugs@FDA approval record — FDA
  2. Zepbound FDA Drugs@FDA approval record — FDA

Clinical Trial Records

  1. ATTAIN-1 clinical trial record — ClinicalTrials.gov
  2. SURMOUNT-1 / SURMOUNT-5 (head-to-head vs semaglutide) clinical trial record — ClinicalTrials.gov

Peer-Reviewed Literature

  1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med 2022;387:205-216 — New England Journal of Medicine
  2. Malhotra A et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA). N Engl J Med 2024;391:1193-1205 — New England Journal of Medicine

Safety Communications

  1. FDA approves first medication for obstructive sleep apnea (Zepbound OSA indication, December 20, 2024) — FDA

Manufacturer Information

  1. Zepbound patient and healthcare provider website — Eli Lilly
  2. Lilly lowers price of Zepbound single-dose vials (December 1, 2025) — Eli Lilly Investor Relations
  3. SURMOUNT-5: Zepbound superior weight loss over Wegovy (May 11, 2025) — Eli Lilly Investor Relations

Reference Entries

  1. Tirzepatide entry on Wikipedia — Wikipedia

This content is for informational purposes only and is not medical advice. Always consult your healthcare provider before making medication decisions. See our full medical disclaimer.